Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049 clinical trials
Also written BI 765049.
Its developmentBy Boehringer Ingelheim, step by step3 company-led studies, furthest phase 1: when each phase was reached, its deals, target and what is ahead.- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 765049
- 3
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or PancreasTerminatedPhase 1Boehringer IngelheimNCT06882746Written as BI 765049How we know
- A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6TerminatedPhase 1Boehringer IngelheimNCT06091930Written as BI 765049How we know
- A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell SurfaceCompletedPhase 1Boehringer IngelheimNCT04752215Written as BI 765049How we know